Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.

Bladder Cancer · 2016 · PMC4927845 · PMID 27376138

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Mutations in several other genes also appear to be more common in MIBC but did not reach statistical significance: ERBB3, CDKN1A, CDKN2A, NFE2L2, TXNIP.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.